News Headlines

  1. Zydus And Formycon Enter Into An Exclusive Partnership For The Licensing And Supply Of Biosimilar To Keytruda® (Pembrolizumab), In US and Canada 12/19/2025

    Zydus Lifesciences Limited (including its subsidiaries and affiliates), an innovation-led life-sciences company, with an international presence, today announced that its wholly owned subsidiary, Zydus Lifesciences Global FZE, United Arab Emirates has entered into a strategic partnership with Formycon AG for the exclusive licensing and supply of checkpoint inhibitor FYB206, a biosimilar of Keytruda®1 (Pembrolizumab) in the USA and Canada market.

  2. The Road To Sustainability: Pharma's Green Evolution At PHARMAP 2026 12/18/2025

    As a key player in global healthcare, the pharmaceutical industry is increasingly responsible for minimising the environmental impact. PHARMAP 2026 (Amsterdam, 20-21 April) is fostering a new wave of green initiatives and innovations, with a dedicated session focused on waste reduction and the development of eco-friendly products.

  3. Minaris And Cell And Gene Therapy Catapult Announce Collaboration To Advance Delivery Methods For Cell And Gene Therapies 12/18/2025

    Minaris, a global cell and gene therapy (CGT) contract development and manufacturing organization (CDMO) and multimodality biosafety testing provider and Cell and Gene Therapy Catapult (CGT Catapult), an independent technology and innovation organization specializing in the advancement of the CGT industry, today announced a collaboration to develop CGT delivery technologies to enable more robust manufacturing processes, improved quality, and lower cost of goods.

  4. AtomVie Global Radiopharma Secures A Supply Agreement With Ionetix Corporation To Accelerate Ac-225 Radiotherapeutics Development 12/18/2025

    AtomVie Global Radiopharma (AtomVie), a global radiopharmaceutical Contract Development and Manufacturing Organization (CDMO) specializing in GMP manufacturing and clinical supply, is pleased to announce a strategic partnership with Ionetix Corporation (Ionetix) to enhance access to clinical-grade Actinium 225 (Ac-225) for its partners worldwide.

  5. CDMO Incog Biopharma Announces $200 Million Manufacturing Expansion In Indiana 12/17/2025

    INCOG BioPharma Services, a leading contract development and manufacturing organization (CDMO), today announced another major expansion with an investment of approximately $200 million in its manufacturing facility in Fishers, Indiana. This investment will significantly increase the company’s injectable drug product manufacturing capacity.

  6. Lifecore Biomedical Signs CDMO Master Services Agreement With New Large Multinational Pharmaceutical Customer 12/17/2025

    Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that it has signed a CDMO master services agreement with a new large global pharmaceutical customer.

  7. Halo Pharma Enhances Manufacturing Capabilities With Macro-Pactor® Investment 12/16/2025

    Halo Pharma, a leading CDMO specializing in pharmaceutical development and manufacturing services, is expanding its manufacturing capabilities at its Whippany, New Jersey facility with the addition of a Gerteis Macro-Pactor®, a versatile roller compactor that enhances the company’s ability to manage complex formulations, improve process efficiency, and deliver consistent solid-dose pharmaceutical products.

  8. Asimov Launches CHO Edge Rapid Pools To Bridge Biologics Discovery And CMC With Predictive Stable Expression 12/16/2025

    Asimov, the synthetic biology company advancing the design and manufacture of therapeutics, today announced the launch of CHO Edge Rapid Pools, a high-throughput stable CHO expression system that brings CMC-grade performance and assurance to biologics discovery teams.

  9. PharmaLogic Announces Successful Supply Of First Cohort Dosing For Ratio Therapeutics' Phase 1/2 Study Of A Novel FAP-Targeted Radiopharmaceutical In Late-Stage Aggressive Sarcomas 12/16/2025

    PharmaLogic Holdings Corp. ("PharmaLogic" or "the Company"), a leading contract development and manufacturing organization (CDMO) specialized in radiopharmaceuticals, announced today that it has successfully supplied the first cohort dosing of Ratio Therapeutics' investigational FAP-targeted radiopharmaceutical, [Ac-225]-RTX-2358, for the ATLAS trial.

  10. INCOG BioPharma Announces $200M Expansion, Growing The Team To Nearly 1,000 Employees 12/16/2025

    INCOG BioPharma Services, a leading contract development and manufacturing organization (CDMO), today announced another major expansion with an investment of approximately $200 million in its manufacturing facility in Fishers, Indiana.